# Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial

> **NCT04721301** · PHASE1 · COMPLETED · sponsor: **University Hospital Heidelberg** · enrollment: 50 (actual)

## Conditions studied

- Colorectal Cancer Metastatic
- Pancreatic Cancer Metastatic

## Interventions

- **COMBINATION_PRODUCT:** Nivolumab plus Ipilimumab plus Maraviroc

## Key facts

- **NCT ID:** NCT04721301
- **Lead sponsor:** University Hospital Heidelberg
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-15
- **Primary completion:** 2023-03-15
- **Final completion:** 2023-03-15
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2023-10-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04721301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04721301, "Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04721301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*